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Previous studies have shown that blocking DLL4
signaling reduced tumor growth by disrupting
productive angiogenesis. We developed selective
anti-human and anti-mouse DLL4 antibodies to
dissect the mechanisms involved by analyzing the
contributions of selectively targeting DLL4 in the
tumor or in the host vasculature and stroma in xeno-
graft models derived from primary human tumors.
We found that each antibody inhibited tumor growth
and that the combination of the two antibodies was
more effective than either alone. Treatment with
anti-human DLL4 inhibited the expression of Notch
target genes and reduced proliferation of tumor cells.
Furthermore, we found that specifically inhibiting
human DLL4 in the tumor, either alone or in combina-
tion with the chemotherapeutic agent irinotecan,
reduced cancer stem cell frequency, as shown by
flow cytometric and in vivo tumorigenicity studies.
INTRODUCTION
Accumulating evidence has suggested that tumors are fre-
quently composed of heterogeneous cell types and that tumor
initiation and growth are driven by a subset of cells, termed
cancer stem cells (CSCs) or tumor-initiating cells (Reya et al.,
2001; Ailles and Weissman, 2007). In this model, tumors can
be viewed as having a hierarchical organization with a tumori-
genic cell population that can self-renew, and thereby proliferate
indefinitely, at the top of the hierarchy. CSCs can also give rise to
more differentiated progeny that comprise the bulk of the tumor,
have reduced proliferative capacity, and are therefore less
tumorigenic (Clarke et al., 2006). Although CSCs share certain
properties with normal stem and/or progenitor cells, CSCs
have accumulated oncogenic mutations and lost normal con-
straints on growth control. Evidence for tumor heterogeneity
and CSCs was first provided in acute myeloid leukemia (AML)
(Lapidot et al., 1994) and more recently extended to several
human solid tumors, for example, breast, brain, prostate, colon,
and pancreatic cancers (Al-Hajj et al., 2003; Singh et al., 2004;
Patrawala et al., 2006; Galli et al., 2004; O’Brien et al., 2007;
Ricci-Vitani et al., 2007; Dalerba et al., 2007; Li et al., 2007).168 Cell Stem Cell 5, 168–177, August 7, 2009 ª2009 Elsevier Inc.Furthermore, several research reports have indicated that
CSCs can be preferentially resistant to many current therapies,
including various chemotherapeutic agents and radiation treat-
ment (Dean et al., 2005; Costello et al., 2000; Matsui et al.,
2004; Bao et al., 2006; Phillips et al., 2006; Dylla et al., 2008).
Thus, therapeutic strategies that effectively target CSCs could
have a major impact on cancer patient survival.
Delta-like 4 ligand (DLL4) is an important component of the
Notch pathway and contributes to stem cell self-renewal and
vascular development. Deletion of a single allele of DLL4 results
in embryonic lethality due to defects in development of the
vasculature (Duarte et al., 2004; Gale et al., 2004; Krebs et al.,
2004). DLL4 overexpression is found in tumor vasculature and
in tumor cells to activate Notch signaling (Patel et al., 2005;
Yan et al., 2001). Previous studies have indicated that inhibition
of DLL4 resulted in broad spectrum antitumor activity in cancer
cell line-based xenograft models (Noguera-Troise et al., 2006;
Ridgway et al., 2006; Scehnet et al., 2007). The antitumor effect
was shown to be the result of dysregulated angiogenesis char-
acterized by increased sprouting in endothelial tip cells leading
to nonfunctional vasculature in the tumor. Thus, inhibiting DLL4
disrupts productive angiogenesis in a manner distinct from tradi-
tional antiangiogenic therapies by causing hyperproliferation of
tumor vessels that leads to a reduction in tumor growth (Swain-
son and Harris, 2007; Thurston et al., 2007). In addition to its role
regulating endothelial cells and tumor vasculature, the Notch
pathway is known to play a key role in stem cell growth and
differentiation in many lineages and tumor types (Wilson and
Radtke, 2006). We developed neutralizing antibodies against
human DLL4 to evaluate the effects of selectively targeting
DLL4 expressed on tumor cells on tumor growth and CSC
frequency. We also developed antibodies to murine DLL4 to
further analyze the effects blocking signaling from DLL4 ex-
pressed in tumor stromal and vascular cells in xenograft models.
The studies presented here focus primarily on early-passage
colon tumor xenograft models. We found that blocking DLL4
selectively in the tumor resulted in a reduction in tumor growth
and tumorigenic cell frequency independent of an angiogenic
mechanism.
RESULTS
Identification and Characterization of Anti-Human DLL4
We first screened monoclonal anti-DLL4 antibodies from a
murine hybridoma library for their ability to inhibit DLL4-induced
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reporter assay in HeLa cells. The antibody 21M18 showed strong
inhibition in this assay and was further characterized. 21M18
binds to humanDLL4 (hDLL4) but does not cross-react tomurine
DLL4 (Figure 1A), and correspondingly blocks human, but not
murine, DLL4 binding to Notch1 receptor in a FACS-binding
assay (Figure 1B). Anti-hDLL4 is completely specific for binding
to DLL4 and does not bind detectably to any other Notch ligand,
DLL1, DLL3, JAG1, or JAG2 (data not shown). Anti-hDLL4 is able
to completely inhibit induction of a Notch-responsive reporter
gene activated by hDLL4 stimulation (Figure 1C). We have deter-
mined the binding dissociation constant (Kd) to be 0.6 nM by
Biacore assay using an Fc-hDLL4 protein containing the entire
extracellular domain of hDLL4. To identify antibodies that recog-
nize specific regions of the DLL4 extracellular domain, epitope
mapping using variousmurine/human chimeras of DLL4 contain-
ing domains 1–6 of the N terminus was preformed. Our initial
evaluation indicated that domains 1 and 2 (Parks et al., 2006)
were important for binding, as replacement of either domain
with the homologousmurine sequence resulted in loss of binding
to 21M18 (see Figure S1 available online). Although the Delta/
Serrate/lag-2 (DSL) domain (Tax et al., 1994), also known as
domain 3, was not sufficient for anti-hDLL4 binding, the pres-
ence of this domain was required for binding of anti-hDLL4
21M18 to hDLL4. Further analysis of amino acids in domains 1
and 2 bymutagenesis showed that amino acids VVP at positions
68, 69, and 71, and K and A at positions 142 and 144were critical
for anti-hDLL4 binding (Figure 1D). Thus, anti-hDLL4 21M18
recognizes a conformational epitope comprised of distinct
regions in the primary sequence of hDLL4.
In Vivo Antitumor Activity of Anti-hDLL4
To determine the antitumor effect of anti-hDLL4 in vivo, we
utilized human xenograft tumor models in NOD-SCID mice for
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Figure 1. In Vitro Characterization of Anti-
DLL4 Monoclonal Antibodies
(A and B) Activity of 21M18 in binding to human or
mouse DLL4 (A) and blocking human or mouse
DLL4 binding to Notch1-expressing cells (B).
Each data point represents the average of two
replicates. 21M18 was found to bind and inhibit
human DLL4, but not mouse DLL4.
(C) Anti-hDLL4 inhibits hDLL4-induced Notch
signaling using a luciferase reporter assay.
(D) Amino acids from mouse DLL4 were
substituted into the human DLL4 protein and
tested for binding anti-hDLL4 in order to map its
epitope. Two separate regions in the primary
sequence were required for binding. One region
is aa 68–71 in domain 1, and the second region is
aa 142–144 in domain 2.
our antibody screening and efficacy
studies. The experiments presented in
this report focus primarily on colon tumor
xenografts. Tumors were directly trans-
planted into mice from patient samples
and were minimally passaged in vivo
without any selection for growth in cell
culture. Importantly, these tumors retain much of the cellular
heterogeneity of primary human tumors and contain CSCs as
well as more differentiated nontumorigenic cells (Dalerba et al.,
2007). The initial xenograft studies of anti-hDLL4 entailed
implantation of tumor cells followed by initiation of treatments
at day 2 (preventative dosing regimen). Using this experimental
paradigm, we found that in OMP-C8, a human colon tumor xeno-
graft derived from a liver metastasis, anti-hDLL4 produced
a decrease in tumor growth (Figure 2A). We then explored the
administration of anti-hDLL4 in combination with several chemo-
therapeutic agents commonly used for colon cancer. Anti-hDLL4
showed additive antitumor activity with 5-FU treatment (data not
shown), and we found that OMP-C8 colon tumors were particu-
larly sensitive to combination of anti-hDLL4 and irinotecan. For
example, irinotecan at a dose of 7.5 mg/kg decreased OMP-
C8 colon tumor volume by 80%, and, importantly, the combina-
tion of irinotecan plus anti-hDLL4 produced increased growth
inhibition compared to the single agents alone (Figure 2A). In
anti-hDLL4-treated OMP-C8 tumors, changes in the expression
of Notch target genesHES1 andATOH1 (Figure 2B) were consis-
tent with the pattern of known antagonists of Notch signaling
such as gamma secretase inhibitors (van Es et al., 2005). Further
analysis showed that the effect of anti-hDLL4 on tumor growth
was associated with a decrease in the frequency of proliferating
cells, as indicated by a reduction of Ki67 expression in treated
tumors, detected by immunohistochemistry (Figure 2C). Since
very limited tumor growth was evident in the animals treated
with the combination of anti-hDLL4 and irinotecan, we then
investigated if tumor growth would resume if treatments were
discontinued. We observed that tumors continued to grow
progressively in the mice previously treated with irinotecan
alone, whereas no tumors emerged and maintained growth in
the animals previously treated with the combination of anti-
hDLL4 and irinotecan (Figure 2D). A similar pattern was observedCell Stem Cell 5, 168–177, August 7, 2009 ª2009 Elsevier Inc. 169
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Figure 2. In Vivo Efficacy of Anti-hDLL4 Antibody 21M18
(A) Effect of control antibody (open circles), anti-hDLL4 (closed circles), irinotecan (dosed at 7.5 mg/kg once per week; open triangles), and the combination of
anti-hDLL4 plus the same dose of irinotecan (closed triangles) on the growth of OMP-C8 colon xenograft tumors in NOD/SCIDmice. Therewere tenmice used per
treatment group; *p < 0.05 versus control Ab group; **p < 0.05 versus irinotecan plus control Ab group.
(B) Effect of anti-hDLL4 on Notch target gene expression in OMP-C8 tumors as determined by quantitative PCR; *p < 0.05 versus control Ab group.
(C) anti-hDLL4 reduces cell proliferation in OMP-C8 tumors, determined by immunohistochemical staining for Ki67, a marker of cell proliferation. The top two
photomicrographs were taken at 203 magnification and the bottom two at 403.
(D) Continuation of the experiment shown in (A) following termination of the irinotecan and anti-hDLL4 treatments. The tumors in the group previously treated with
irinotecan alone (open triangles) continued to grow, while the tumors in the group previously treatedwith anti-hDLL4 plus irinotecan (closed triangles) did not grow
during the course of the experiment. Data are expressed as mean + SEM.in OMP-C9 and OMP-C17 (Figure S2). Thus the combination of
anti-hDLL4 and irinotecan resulted in increased antitumor
activity in several colon tumor xenografts, relative to irinotecan
alone. Consistent with our observations using the preventative
dosing regimen, we found that 21M18 was efficacious alone
and in combination with irinotecan in treating established
OMP-C8 colon tumors (Figure S3).
Effect of Anti-hDLL4 on Tumor Recurrence
We developed a dosing regimen that would allow us to test the
effect of anti-hDLL4 on tumor recurrence following chemothera-
peutic treatment. In this tumor recurrence model, we treated
mice bearing colon tumor xenografts of 200–500 mm3 with
45 mg/kg irinotecan twice a week for 4–5 weeks. As seen in Fig-
ure 3A, this high dose of irinotecan induced OMP-C8 tumor
regression; however, tumors reappeared about 25 days after
treatment with irinotecan was terminated and grew progres-
sively. Inclusion of anti-hDLL4 during irinotecan treatment did
not affect the rate of irinotecan-mediatedOMP-C8 tumor regres-
sion but significantly delayed tumor recurrence following termi-170 Cell Stem Cell 5, 168–177, August 7, 2009 ª2009 Elsevier Inc.nation of the chemotherapy (Figure 3A). Similar results were
observed in an additional colon tumor model, OMP-C17
(Figure S4).
Effect of Anti-hDLL4 on Tumorigenic Cells
It has been proposed that CSCs are preferentially resistant to
many standard therapies and that CSCs mediate tumor recur-
rence following such treatments (Dean et al., 2005; Bao et al.,
2006). To determine whether the observed synergistic growth
inhibition and delay in tumor recurrence by the combination of
anti-hDLL4 and irinotecan was a result of these agents reducing
tumor-initiating cell frequency, the CSC population was quanti-
fied in regressing tumors in three ways: flow cytometry, in vitro
colony formation, and in vivo tumor growth. Tumors were har-
vested after 3 weeks of treatment at the point when they were
reduced by 50% of the initial volume during irinotecan-induced
tumor regression (as in Figure 3A). Flow cytometric analysis
showed that cells expressing cell markers associated with
tumorigenic colon cancer cells, ESA+/CD44+/CD166+ (Dalerba
et al., 2007), were increased from 28% in the control group to
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shown in Figure S5). In contrast, treatment with anti-hDLL4 re-
sulted in a 50%decrease in the ESA+/CD44+/CD166+ population
compared to the control group. Notably, the combination of anti-
hDLL4 and irinotecan further decreased the percentage of this
triple-positive cell population in treated tumors (Figure 3B).
Tumor cells from the four treatment groups were processed to
generate single-cell suspensions and assayed for their ability
form colonies in vitro. This type of assay, a single-cell deposi-
tion-limiting dilution assay (SCD-LDA), has been used in the
hematopoietic stem cell field to quantify normal and leukemic
stem cells (Breems et al., 1994). We adapted this assay for
studying epithelial tumor cells and have established culture
conditions that support the growth over several weeks of tumor-
igenic, but not nontumorigenic, cells (Dylla et al., 2008). Irinote-
can treatment was found to increase the percentage of cells
capable of forming colonies, while the colony formation by tumor
cells harvested from mice previously treated with the combina-
tion of anti-hDLL4 plus irinotecanwas lower than both the control
and the irinotecan alone groups (Figure 3C).
A functional test to determine CSC frequency is to transplant
tumor cells from treated mice to another set of mice and quantify
the number of cells required to generate new tumors by limiting
dilution assay (LDA) (Wang et al., 1997). Equal cell numbers from
each of the four treatment groups were injected into mice at four
different cell doses, and tumor growth was assessed after
86 days (Figure S6). The frequency of tumor growth observed at
the various cell numbers allows the determination of CSC
frequency. As seen in Figure 3D, control mAb-treated tumors
had a CSC frequency of approximately 1/160. Irinotecan-treated
tumors had an approximately 2-fold higher CSC frequency
compared tocontrol. In contrast, treatmentwith anti-hDLL4alone
decreased the percentage of CSCs compared to control by
approximately 2-fold. Strikingly, the combination of anti-DLL4
and irinotecan produced a further decrease in CSC frequency,
approximately 5-fold lower than the control group and 9-fold
lower than tumors treated with irinotecan alone (Figure 3D).
Additionally, we addressed the question of how treatment with
anti-hDLL4 and irinotecan affected tumorigenicity by serially
transplanting sorted cells derived from tumors after in vivo treat-
ment. We purified tumor cells expressing colon CSC markers
(ESA+/CD44+/CD166+) (Dalerba et al., 2007) and injected
100 cells per mouse from either control Ab, irinotecan plus
control Ab, or irinotecan plus anti-hDLL4-treated tumors. Cells
from the first two groups grew readily and formed large tumors,
whereas cells from tumors previously treated with the combina-
tion of chemotherapy and anti-hDLL4 exhibited reduced tumor
growth frequency and rate (Figures 3E and 3F). Thus, the effect
of anti-hDLL4 on reducing tumorigenicity is apparent not only
when analyzing the whole tumor cell population but also when
enriching for cells expressing CSC markers.
Effect of Anti-hDLL4 on Gene Expression in CSCs
To investigate the mechanism of action of anti-hDLL4 on
reducing cancer stem cell frequency, we then determined the
effect of anti-hDLL4, irinotecan and the combination on gene
expression in sorted cells expressing colon CSC markers
(ESA+/CD44+/CD166+) (Dalerba et al., 2007) as well as in nontu-
morigenic cells (ESA+/CD44/CD166) from OMP-C8 tumors.DLL4 was expressed at the RNA level in both cell populations,
and we found that anti-hDLL4 treatment resulted in repression
of HES1 and activation of ATOH1 expression in both cell popu-
lations (Figures 4A and 4B) similar to the effect seen in the whole
tumor (Figure 2B). Thus, anti-hDLL4 appears to have a direct
effect in modulating Notch signaling in the CSC-enriched
subpopulation within the tumor. We also found that anti-hDLL4
modulated the expression of other genes that shed light on its
mechanism of action. For example, we found that anti-hDLL4
induced the expression of chromogranin A (CHGA), a marker
of endocrine differentiation in colon cells (Hendy et al., 1995).
Genes that regulate apoptosis were altered by anti-hDLL4. For
example, while irinotecan treatment induced the expression of
antiapoptotic genes such as HSPA6 and BIRC3, anti-DLL4
reversed this effect in the combination group. The genes
mentioned above were regulated equivalently in both CD44+/
CD166+ cells and CD44/CD166 cells. In contrast, certain
genes were found to be differentially regulated in the CSC-
enriched cells versus the nontumorigenic cells, including the
proapoptotic gene PDCD4, the Wnt inhibitors DACT1 and
AXIN2, andgenes involved in oxidative stress,FOXO1 andTXNIP.
Targeting Murine and Human DLL4 in Xenografts
Our antibody, 21M18, recognizes human but not rodent DLL4.
Therefore, with this antibody we are not able to assess the
impact of blocking DLL4-Notch signaling in the tumor stroma
and vasculature as previously described (Noguera-Troise et al.,
2006; Ridgway et al., 2006). To dissect the mechanisms involved
in anti-DLL4 inhibition of tumor growth, we developed an anti-
mouse DLL4 antibody, designated 21R30, which is capable of
blocking binding and signaling of murine but not human DLL4
(Figure S7). We confirmed that this anti-mouse DLL4 antibody
has antitumor activity through deregulating tumor angiogenesis.
Similar to previous studies, tumors treatedwith anti-mouse DLL4
showed increased tumor vasculature as seen by anti-CD31
staining (Figure 5A). In contrast, there was no evidence for endo-
thelial cell hyperproliferation after anti-hDLL4 treatment. The
combination of antibodies also showed an effect on increasing
endothelial cell staining similar to anti-mDLL4 (Figure 5A). We
then tested the anti-mDLL4 and anti-hDLL4 antibodies individu-
ally and in combination for their effect on C8 tumor growth and
found that each antibody reduced tumor growth by approxi-
mately 50%, and the combination of the two antibodies
produced additive antitumor efficacy (Figure 5B). We next tested
the effect of chemotherapeutic treatment in the context of inhib-
iting DLL4 in both the stroma and the tumor, and found irinotecan
combined with anti-hDLL4 and anti-mDLL4 resulted in additive
antitumor activity and regression of established C8 tumors
(Figure 5C).
Activity of Anti-DLL4 in Breast Tumors
Previous studies in this paper have focused on colon tumors. We
have also observed that blocking DLL4 in both the tumor and in
the stroma/vasculature has antitumor efficacy in a wide range of
human tumor xenografts from various tumor types including
colon, breast, lung, and pancreas. An example in a breast tumor
xenograft is shown in Figure 6. Established UM-PE13 breast
tumors were treated with high-dose taxol (paclitaxel) to reduce
tumor volume together with either a control Ab or theCell Stem Cell 5, 168–177, August 7, 2009 ª2009 Elsevier Inc. 171
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Figure 3. Effect of Anti-hDLL4 on Colon Tumor Recurrence
(A) Treatments were initiated when OMP-C8 colon tumors were approximately 200 mm3 (left arrow). Irinotecan was dosed at 45 mg/kg twice per week, either
together with control Ab (open circles; n = 12) or together with anti-hDLL4 (closed circles; n = 11). Irinotecan treatments were stopped at day 60 (right arrow),
and the antibody treatments continued. The rates of tumor growth in the two groups are shown. Anti-hDLL4 reduced the rate of tumor recurrence.
(B) Established tumors were treated for 2 weeks with either control Ab, anti-hDLL4, irinotecan (45 mg/kg), or anti-hDLL4 plus irinotecan and analyzed by flow
cytometry for the expression of the CSC markers CD44, CD166, and ESA. Five tumors from each treatment were analyzed. *p < 0.05 versus control Ab group;
**p < 0.05 versus irinotecan plus control Ab group.
(C) Tumors previously treated as described in (B) were analyzed for their ability to form colonies when cultured in vitro.
(D) Tumors treated as described in (B) were analyzed for CSC frequency by serial in vivo transplant, LDA. There were ten mice per group and four cell doses
analyzed. The appearance of tumors on day 86 was used to calculate the tumor-initiating cell frequency. Anti-hDLL4 treatment (open bars) reduced CSC172 Cell Stem Cell 5, 168–177, August 7, 2009 ª2009 Elsevier Inc.
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this pair of antibodies had a dramatic effect in delaying tumor
regrowth after cessation of the taxol treatment (Figure 6A). We
observed no significant regrowth of tumors for approximately
80 days after stopping chemotherapeutic treatments. UM-PE13
tumors treated with either control Ab, taxol plus control Ab,
anti-hDLL4 plus anti-mDLL4, or the combination of taxol and
the anti-DLL4 antibodies were analyzed by serial transplant,
LDA to quantify tumor-initiating cell frequency. Taxol treatment
was found to increase CSC frequency approximately 3-fold,
while inhibiting DLL4 decreased CSC frequency, either alone
or, more significantly, in combination with taxol (Figure 6B).
A
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Figure 4. Effect of Anti-hDLL4 on Gene Expression in Sorted En-
riched CSC and Non-CSC Populations
OMP-C8 tumors treated with either control Ab (black bars), irinotecan (red), or
anti-hDLL4 (blue), or the combination of irinotecan and anti-hDLL4 (green).
After 2 weeks of treatment, tumors were processed, and tumor cells were
sorted by flow cytometry into CD44+CD166+ andCD44-CD166 populations.
Levels of gene expression determined by quantitative PCR in the double-posi-
tive cells (A) and double-negative cells (B) are shown. Values are relative to the
control Ab-treated group.DISCUSSION
Our findings demonstrate that blocking DLL4 signaling inhibits
tumor growth through multiple mechanisms, including a reduc-
tion in CSC frequency. In addition to the previously described
effect on deregulating angiogenesis by targeting DLL4 in the
vasculature, we show that selectively inhibiting DLL4 signaling
in human tumor cells with anti-hDLL4 21M18 leads to a decrease
in colon tumor growth, a delay in tumor recurrence after chemo-
therapeutic treatment, and a decrease in the percentage of
tumorigenic cells. While inhibition of DLL4-Notch signaling is a
new and promising strategy for cancer treatment, the utility of
disrupting angiogenesis via this mechanism (Thurston et al.,
2007) has yet to be proven effective in the clinic. DLL4 blockade
has been shown to increase proliferation of endothelial cells;
however, the resulting vessels are not perfused by intravascular
tracers, such as lectin, suggesting that these vessels lack a func-
tional lumen. An interesting question yet to be resolved concerns
the long-term fate of this abnormal neovasculature and whether
it could ever be normalized into functional tumor vasculature.
Further experiments and future clinical testing are required to
address this important issue.
Understanding the molecular mechanisms involved in the
effect of anti-hDLL4 on tumor-initiating cell frequency is an
important question. It is possible that DLL4-Notch signaling is
required for the self-renewal ability of the CSCs and maintains
the tumorigenic cells in amore undifferentiated cell state. Consis-
tent with this possibility is the repression of HES1 observed in
tumor cells after anti-hDLL4 treatment. HES1 expression has
been shown to be important in maintaining cells in an undifferen-
tiated, pluripotent state (Sang et al., 2008). Conversely, upregula-
tion of ATOH1 is indicative of differentiation of colon cells to
mucin-secreting goblet cells, and ATOH1 has recently been
shown tohave theproperties of a tumor-suppressor gene in colo-
rectal cancer (Bossyut et al., 2009). Anti-hDLL4 treatment also
induced expression of CHGA, a known marker for endocrine
cell differentiation in various organs including colon (Hendy
et al., 1995). Significantly, we observed regulation of Notch target
genes, HES1 and ATOH1, after anti-hDLL4 treatment in RNA
prepared from whole tumors (Figure 2B) and in FACS-sorted
tumorigenic and nontumorigenic cells (Figures 4A and 4B).
Thus, anti-hDLL4 can directly regulate Notch signaling in the en-
riched tumorigenic CSC subset of cells within the tumor. In addi-
tion to promoting differentiation of stem/progenitor cells, repres-
sion of DLL4-Notch signaling in CSCs may also promote cell
death or inhibit proliferation of the tumorigenic cells, particularly
in combination with chemotherapeutic agents.
We observed that irinotecan treatment induces a stress
response in tumor cells and an increase in the expression of
certain antiapoptotic genes suchasHSPA6 (also knownas induc-
ible HSP70) and BIRC3 (also known as cIAP2). Anti-hDLL4frequency relative to control-treated tumor (black bars). Irinotecan treatment (cross-hatched bar) increased CSC frequency, and the combination of anti-hDLL4
plus irinotecan group (gray bar) resulted in tumors with a lower CSC frequency than both the control and irinotecan alone groups. *p < 0.05 versus control Ab
group; **p < 0.05 versus irinotecan plus control Ab group.
(E) Serial transplant of tumor cells from treated animals from the experiment shown in (A). One hundred CD44+CD166+ cells were injected into ten animals each,
and tumor growth was monitored over 84 days.
(F) Individual tumor measurements on day 84 from each of the ten animals shown in the groups in the serial transplant experiment (E) are shown. Data are
expressed as mean + SEM.Cell Stem Cell 5, 168–177, August 7, 2009 ª2009 Elsevier Inc. 173
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tumor cells to cell death in response to the chemotherapeutic
treatment.
All the genes discussed above were regulated in a similar
manner to the tumorigenic CD44+/CD166+ and nontumorigenic
CD44/CD166 cell populations. Interestingly, certain genes
were found to be differentially regulated in the two cell popula-
tions. For example, the proapoptotic tumor suppressor gene
PDCD4 (Wang et al., 2008) was found to be induced by the
combination of anti-DLL4 and irinotecan in the enriched tumori-
genic cell population, but not the CD44/CD166 cells. We also
observed selective activation of the Wnt pathway inhibitors
A
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Figure 5. Effect of Anti-hDLL4 in Combina-
tion with Anti-Mouse DLL4
(A) Effect of anti-DLL4 antibodies on tumor vascu-
lature as shown by anti-CD31 staining. Tumors
treated with anti-mouse DLL4, 21R30 show
increased anti-CD31 staining, while tumors treated
with anti-hDLL4 look similar to control.
(B) Established OMP-C8 tumors were treated with
either control Ab (open circles), anti-hDLL4 (filled
circles), anti-mDLL4 (open triangles), or both anti-
bodies (filled triangles). There were ten animials in
each treatment group; *p < 0.05 versus control
Ab group.
(C) Established OMP-C8 tumors were treated with
either control Ab (open circles), anti-hDLL4 plus
anti-mDLL4 (filled triangles), irinotecan (dosed at
7.5 mg/kg once per week) plus control Ab (open
triangles), or the combination of irinotecan plus
anti-hDLL4 and anti-mDLL4 (filled circles). *p <
0.05 versus control Ab group; **p < 0.05 versus iri-
notecan plus control Ab group. Data are expressed
as mean + SEM.
AXIN2 and DACT1 in the tumorigenic
cells. AXIN2 is a well-characterized inhib-
itor of canonical Wnt signaling through
b-catenin (Jho et al., 2002), and DACT1
(also known Dapper 1) encodes a Dishev-
eled-interacting protein that also blocks
Wnt signaling (Zhang et al., 2006). The
Wnt-b-catenin pathway is known to be
important is maintaining normal and
CSCs in the colon (van Es et al., 2005).
These data provide evidence for crosstalk
between the Notch and Wnt pathways in
CSCs, which has been observed in other
settings (for example, Phng et al., 2009).
Certain genes regulated by oxidative
stress were also found to be regulated
by anti-DLL4, including FOXO1 and
TXNIP. The FoxO family of transcription
factors has been previously found to be
required for maintenance of hemato-
poetic stem cells and protects these cells
from oxidative stress (Tothova et al.,
2007). Resistance to oxidative stress has
recently been shown to be a property of
CSCs, and FOXO1 and TXNIPwere found
to upregulated in tumorigenic cells (Diehn et al., 2009). Reduc-
tion of expression of these genes after anti-DLL4 treatment
provides further insight into the mechanism of action in the
tumorigenic cell subset.
Inhibition of DLL4-Notch signaling in tumor cells also appears
to affect proliferation of the nontumorigenic, or bulk tumor, cells
as demonstrated by the effect of anti-hDLL4 on the number of
Ki67-positive cells. The CSC frequency of C8 tumor xenografts
was determined to be less than 1% by LDA (Figure 3D), while
anti-hDLL4 reduced the number of proliferating cells in tumors
by a far larger extent, apparently greater than 50% (Figure 2C).
This is consistent with our finding that anti-DLL4 treatment174 Cell Stem Cell 5, 168–177, August 7, 2009 ª2009 Elsevier Inc.
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as well as the CD44+/CD166+ tumorigenic cells.
This study presents an experimental approach and highlights
the utility of using human tumor xenografts to study the effect
of drug treatments. An advantage of these models over conven-
tional cell line-based models is that the tumor-derived xeno-
grafts retain much of the cellular heterogeneity of original tumor.
Importantly, use of the human tumor xenografts allows the quan-
tification of a drug’s effect on tumor-initiating cell frequency by
carrying out in vivo serial transplantation of cells from treated
tumors. Although technically demanding and time consuming,
the in vivo LDA is a very powerful, functional assay that makes
no assumptions about the frequency, flow cytometry marker
profile, or heterogeneity of the tumor-initiating cell population
A
B
Figure 6. Effect of Anti-hDLL4 and Anti-mDLL4 in Combination with
Paclitaxel on Breast Tumor Recurrence and Cancer Stem Cell
Frequency
(A) Established UM-PE13 tumorswere treatedwith either control Ab plus pacli-
taxel (open circles) or a mixture of anti-hDLL4 and anti-mDLL4 plus paclitaxel
(filled circles). Paclitaxel was dosed at 15 mg/kg twice per week. Paclitaxel
treatments were stopped at day 75, and the antibody treatments were
continued. Tumor growth recurred in the control group after the cessation of
paclitaxel treatments, but not in the anti-DLL4 group.
(B) Tumors were harvested from the experiment shown in (A) along with tumors
treated with control Ab alone or anti-hDLL4 plus anti-mDLL4 and analyzed for
CSC frequency by serial transplant, in vivo limiting dilution analysis. There
were ten mice per group, and three cell doses were analyzed for each group
(50, 150, and 500 cells). The appearance of tumors onday 75was used to calcu-
late the tumor-initiating cell frequency. Anti-hDLL4 + anti-mDLL4 treatment
(open bar) reduced CSC frequency relative to the control Ab-treated tumors
(black bar). Paclitaxel treatment (cross-hatched bar) increased CSC frequency,
and the combination of anti-hDLL4 plus irinotecan group (gray bar) resulted in
tumors with a lower CSC frequency than both the control and irinotecan alone
groups. *p < 0.05 versus control Ab group; **p < 0.05 versus irinotecan plus
control Ab group. Data are expressed as mean + SEM.within a tumor and therefore is widely applicable to the preclin-
ical study of many different tumor types and therapeutic agents.
A key challenge in the field is to find surrogate markers that reli-
ably correlate with tumor-initiating cell frequency across a broad
range of tumors. This advance would enable the quantification of
CSCs in clinical tumors samples—for example, before and after
treatment, an important application for which the LDA is not
a practical option.
We provide evidence that it is possible to increase or decrease
tumorigenic cell frequency in treated tumors. For example, treat-
ment with the chemotherapeutic agents irinotecan or taxol, while
effective at reducing tumor volume, increased the frequency of
tumorigenic cells. These data provided further experimental
support for a widely held hypothesis in the field proposing that
CSCs are preferentially resistant to many current therapies
(Dean et al., 2005; Wicha et al., 2006) and are consistent with
other studies (Bao et al., 2006; Dylla et al., 2008). Our findings
have important potential implications in cancer treatment and
drug discovery. Agents that reduce cancer cell frequency hold
the promise of improving cancer treatment by delaying or pre-
venting tumor recurrence and reducing the metastatic spread
of disease. In particular, blocking DLL4 function is an attractive
strategy for novel therapeutics, since this approach attacks the
tumor through multiple mechanisms including inhibiting produc-
tive angiogenesis, inhibiting proliferation of bulk tumor cells, and
reducing CSC frequency.
EXPERIMENTAL PROCEDURES
Antibodies
Anti-human DLL4 antibodies including 21M18 were generated by immunizing
mice with purified human DLL4 (an Fc-DLL4 fusion protein containing the
entire extracellular domain of DLL4), derived from a baculovirus expression
system, followed by hybridoma generation and characterization. For produc-
tion of 21M18, the hybridoma cells were injected in mice intraperitoneally, and
antibody was purified from the ascites fluid. Anti-mouse DLL4 antibodies,
including 21R30, were generated by panning a phage display library obtained
from Morphosys (Rothe et al., 2008). DNA fragments encoding the fAb gener-
ated from the phage display libraries were subcloned into a full-length IgG
expression vector, and the antibody was expressed in CHO cells and purified.
The negative control Ab was 1B711, a murine monoclonal directed against
dinitrophenol, (also known as anti-hapten) and obtained from the American
Type Tissue Collection (ATCC).
Generation of Human and Murine DLL4 Stable Cell Lines
Human and murine DLL4 overexpressing cells were generated by transfecting
HEK293 cells (ATCC) with FuGENE 6 (Roche) and either full-length human
DLL4 (amino acids 1–685) or murine DLL4 (amino acids 1–686) in pcDNA 3.1
(Invitrogen) and selected with G418 for individual clones.
Characterization of Anti-DLL4 Antibodies
Luciferase reporter assays were carried out in HeLa cells (obtained from
ATCC) that stably express human Notch2. Cells were cotransfected with
pGL4 luc (Promega) driven by a synthetic 83 CBS promoter element,
MAML, and pCMVRenilla (Promega) as a transfection control. Cells were incu-
bated with 100 ng hDLL4 ligand (R&D Systems) coated on 96-well optical
plates and assayed 18 hr later using the Dual-Glo luciferase assay reporter
system (Promega). Antibody binding to cells was determined by incubation
of cells on ice with indicated antibody concentrations and detected by goat
anti-mouse PE (Caltag). Ligand/receptor blocking studies were done by first
incubating the cells with the indicated antibodies, then adding hN1 10–15 Fc
(a humanNotch1 peptide corresponding to amino acids 375–601 (which corre-
spond to EGF repeats 10–15) in-frame with the human Fc constant region),Cell Stem Cell 5, 168–177, August 7, 2009 ª2009 Elsevier Inc. 175
Cell Stem Cell
Anti-DLL4 Reduces Cancer Stem Cell Frequencywhichwas detected by goat anti-human Fc PE (Jackson Immunoresearch) and
analyzed by flow cytometry (FACS Calibur, Becton Dickinson).
Epitope Mapping
Mammalian expression plasmid vectors comprising a CMV promoter up-
stream of polynucleotides that encode fragments of the extracellular human
DLL4 domain ormurine/human chimeras as Fc fusion proteins were generated
using standard recombinant DNA technology. Recombinant proteins were
then expressed in cultured HEK293 cells by transient transfection, and condi-
tioned medium was collected and used in ELISA assay to identify the region of
human DLL4 required for interaction with 21M18.
Xenograft Models
The establishment and characterization of in vivo CSC-driven colon and breast
xenograft models were described previously (Dalerba et al., 2007). Tumors
were passaged in vivo fromonegeneration ofmice to thenextwithout any inter-
vening cell culture. Tumor cells were stored at 80C. Experiments for testing
antibodies were initiated from frozen cell stocks. Breast tumors fromUM-PE13
were used at passage 5. Passage 2 was used for all OMP tumors (C8, C9, and
C17). In general, there were ten animals used for each treatment group.
Immunohistochemistry
Tissue samples were either stored in formalin for immunohistochemical anal-
ysis or frozen in optimal cutting temperature (OCT) medium for immunofluore-
sence. For IHC, specimens were embedded in paraffin, and 5 micron tumor
sections were stained with anti-CD31 antibody using standard protocols (Vec-
tastain kit, Vector Labs).
Flow Cytometric Analysis
Single-cell suspensions obtained fromcontrol and treated tumorswere stained
with stem cell markers and analyzed by FACS (BD Biosciences) for their
expression of epithelial specific antigen (ESA or EpCAM), CD44, CD166.
In Vitro Culture
Plates (96-well) were prepared to accept human tumor cells by preplating
either Mitomycin-C-treated 3T3 fibroblasts or murine embryonic fibroblasts
in DMEM +10% fetal calf serum 24 hr prior to experiment initiation. Immedi-
ately prior to depositing individual human tumor cells into these plates in
limiting dilution, the media was replaced with serum-free Medium-D (3:1 low
glucose DMEM:F-12 Media, B27 supplement, ITS-X, Pen/Strep [all from Invi-
trogen, Carlsbad, CA] and 0.5 mg/mL hydrocortisone [Stem Cell Technologies,
Vancouver, BC]), supplemented with 20 ng/mL bFGF and EGF, 5 u/mL heparin
and 13 106 u/mL LIF. After cell deposition, plates were gently spun at 500 rpm
for 5 min at room temperature to promote cell attachment. When cultured
in vitro for more than 7 days, media was changed weekly.
In Vitro Limiting Dilution Assay
ToevaluateCSC frequency in vitro, cells were seededby fluorescence-activated
cell sorting (FACS) into 96-well plates prepared as described above at cell doses
of 40, 120, 360, and 720 cells per well (24 wells per dose) and incubated at 37C/
5%CO2/5%O2 for 21 days. Wells with colony growth were then determined by
visual inspection. Based on frequency of wells with no colony growth, CSC
frequency was determined using Poisson distribution statistics and the L-Calc
Version1.1softwareprogram(StemCellTechnologies, Inc.,Vancouver,Canada).
In Vivo Limiting Dilution Assay to Determine Cancer Stem
Cell Frequency
For the experiment shown in Figure 3D, OMP-C8-bearing animals were treated
with Control Ab, 1B711, anti-hDLL4, irinotecan, or the combination of anti-
hDLL4 and irinotecan. Control and treated tumors were then harvested after
3 weeks, when the irinotecan-treated tumors had regressed to approximately
50% of their volumes before treatment. The harvested tumors from each treat-
ment group were pooled and processed to dissociate into single cells. Tumor
cells were then incubated with biotinylatedmouse antibodies (a-mouse CD45-
biotin 1:200 dilution and rat a-mouse H2Kd-biotin 1:100 dilution, BioLegend,
San Diego, CA) on ice for 30 min followed by addition of streptavadin-labeled
magnetic beads (Invitrogen, Carlsbad, CA) to remove mouse cells. Some
portionof cells (about 300,000cellsper sample)wasprocessed for phenotyping176 Cell Stem Cell 5, 168–177, August 7, 2009 ª2009 Elsevier Inc.analysis as described in the Flow Cytometry Analysis section, and for subse-
quent RNA purification, the remaining human cells in the suspension were
collected, counted, and diluted to appropriate cell doses (50, 100, 300, and
900 cells), mixed in the mixture of 1:1 (v/v) FACS buffer (Hank’s balanced salt
solution [HBSS] supplemented with 2% heat-inactivated fetal bovine serum
and 20 mM HEPES) and Matrigel, and injected subcutaneously in NOD/SCID
mice (10 mice per cell dose per treatment group). Tumors were allowed to
grow for 86 days. The individual tumor measurements are shown in Figure S6.
Tumor-initiating cell frequencywas calculated using the L-calc program (Stem-
Cell Technologies Inc.). The experiment shown in Figure 6B with UM-PE13
breast tumors was carried out in a similar way as described above. The cell
doses used were 50, 150, and 500 cells from each of the experimental groups.
Data Analysis
Data are expressed as mean ± SEM. Differences in mean values between
groups were analyzed by nonparametric t test. Multiple comparisons used
one-way ANOVA test with post hoc t test comparison. Differences of p <
0.05 were considered significantly different. Software for statistical analysis
was by GraphPad Prism4 (GraphPad Software Inc).
SUPPLEMENTAL DATA
SupplementalData includesevenfiguresandcanbe foundwith thisarticleonline
at http://www.cell.com/cell-stem-cell/supplemental/S1934-5909(09)00228-8.
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